Limbus stem cells
Reading File
Finding Sources
Searching PubMed
"limbal stem cells" AND cornea
Finding Sources
Searching PubMed
"limbal stem cell deficiency" AND transplantation
Reading File
Reading File
Reading File
Reading File
Reading Article
PMID: 38813737
Searching the Web
limbal stem cells biology niche markers ABCG2 p63 corneal regeneration 2024 2025
Here is a comprehensive overview of limbal stem cells (LSCs):
Limbal Stem Cells (LSCs)
What Are They?
Limbal stem cells are tissue-specific adult stem cells located at the limbus - the junction between the transparent cornea and the opaque conjunctiva/sclera. They sit in the basal layer of the limbal epithelium, housed within specialized anatomical structures called the Palisades of Vogt (radially oriented ridges at the corneoscleral junction).
They are the sole source of corneal epithelial renewal throughout life. The corneal epithelium turns over completely every 7-10 days, making LSCs among the most active stem cell populations in the body.
Cell Biology
Lineage Hierarchy
LSCs give rise to a three-tier cell hierarchy:
| Cell Type | Characteristics |
|---|---|
| Limbal stem cells | Undifferentiated, slow-cycling, self-renewing |
| Transient amplifying cells (TACs) | Basal corneal epithelial cells; divide rapidly |
| Wing cells | Post-mitotic; move toward surface |
| Superficial squamous cells | Terminally differentiated; shed into tear film |
This is described in Kanski's as: "Progeny of corneal stem cells divide and differentiate to form basal corneal epithelial cells (transient amplifying cells) that differentiate into wing cells (post-mitotic cells) and, finally, superficial squamous cells (terminally differentiated cells)."
Key Molecular Markers
LSCs are identified by:
- p63 / ΔNp63α - the most specific nuclear transcription factor marker; expressed in basal limbal epithelium but absent from central corneal epithelium
- ABCG2 (ATP-binding cassette transporter G2) - a side population marker; also expressed by LSCs
- N-cadherin, vimentin, integrin-α9 - additional markers
- Low expression of CK3/CK12 (differentiation markers) - LSCs are CK3/CK12 negative
The Limbal Niche
The LSC "niche" is the local microenvironment that regulates stem cell survival, quiescence, and proliferation. It includes:
- Limbal stroma (mesenchymal cells, melanocytes)
- Extracellular matrix (collagen, fibronectin, laminin)
- Limbal vasculature and innervation
- Paracrine signaling molecules (EGF, KGF, Wnt, Notch pathways)
Disruption of the niche - not just the cells themselves - can cause or perpetuate limbal stem cell deficiency (LSCD).
Limbal Stem Cell Deficiency (LSCD)
LSCD occurs when LSCs are destroyed or dysfunctional, allowing conjunctival epithelium to migrate over and colonize the cornea (conjunctivalization).
Causes
| Category | Examples |
|---|---|
| Congenital | Aniridia, ectodermal dysplasia |
| Traumatic | Chemical burns (alkali > acid), thermal burns, radiation |
| Inflammatory | Stevens-Johnson syndrome, ocular cicatricial pemphigoid |
| Iatrogenic | Contact lens overwear, prior surgery, mitomycin-C use |
| Infectious | Severe microbial keratitis |
Signs of LSCD (Kanski's)
- Conjunctivalization of the cornea with goblet cells (confirmed by impression cytology with PAS stain or anti-CK19 monoclonal antibody)
- Superficial and deep corneal vascularization
- Fibrovascular pannus formation
- Persistent epithelial defects
- Corneal scarring
Key diagnostic clue: Goblet cells on the corneal surface (normally absent) detected by impression cytology = pathognomonic for LSCD.
Treatment of LSCD
Medical (early/mild disease)
- Discontinue contact lens wear
- Preservative-free artificial tears and lubricating ointment
- Punctal occlusion
- Short course topical steroids (loteprednol 0.5%, fluorometholone 0.1%)
- Autologous serum drops (20% q.i.d.)
Surgical - LSC Grafting (moderate-severe disease)
Surgery follows a principle: treat all associated abnormalities first (lid disease, conjunctival scarring, elevated IOP), then restore the epithelial surface.
| Scenario | Procedure |
|---|---|
| Partial LSCD | Selective (sector) epithelial debridement + sector limbal transplant |
| Total unilateral LSCD | Auto-limbal transplantation from fellow eye (procedure of choice) |
| Total bilateral LSCD | Allograft from living related donor or cadaver donor |
Sources of Donor Tissue
- Conjunctival-limbal autograft (CLAU) - from the fellow healthy eye; avoids rejection, no immunosuppression needed
- Keratolimbal allograft (KLAL) - from living related or cadaveric donor; requires systemic immunosuppression
- Cultivated Limbal Epithelial Transplantation (CLET) - ex vivo expansion of small biopsy of patient's (or donor's) LSCs on an amniotic membrane carrier, then transplanted; minimizes harm to the donor eye
Important caveat (Kanski's): In patients with bilateral disease (Stevens-Johnson syndrome, ocular cicatricial pemphigoid), donor tissue must not be taken from the unaffected eye (autologous) - there is no "unaffected" eye.
Emerging Therapies (2024-2025)
From [Bonnet et al., 2024 (PMID: 38813737)], the current landscape includes:
- CLET under xenobiotic-free conditions - a prospective early-stage trial showed feasibility and safety of culturing LSCs without animal-derived products
- Mesenchymal stem cells (MSCs) - first clinical trials showed short-term benefit, but long-term efficacy is disappointing
- Induced pluripotent stem cells (iPSCs) - being differentiated into corneal epithelial-like cells; still experimental
- Niche rejuvenation - targeting the limbal microenvironment pharmacologically to rescue residual LSCs (important because most LSCD eyes retain some residual LSCs)
- Standardized staging - efforts to standardize LSCD diagnosis/grading to allow comparison of treatment outcomes across studies
Clinical Importance in Context
LSC transplantation is often combined with or followed by:
- Amniotic membrane grafting (to support epithelialization)
- Keratoplasty for corneal scarring (lamellar preferred over penetrating in LSCD)
- Keratoprosthesis (e.g., Boston KPro) in end-stage disease when conventional grafting is not viable
Even after successful LSC transplantation, prognosis is guarded in bilateral disease with underlying dry eye or lid abnormalities, as noted in The Wills Eye Manual.
Sources:
- Kanski's Clinical Ophthalmology, 10th ed. (LSC grafting, LSCD signs, surgical algorithm)
- The Wills Eye Manual (LSCD management protocol)
- Bonnet C et al., Curr Opin Ophthalmol 2024 - Limbal stem cell therapy (PMID: 38813737)
- Bonnet C et al., Exp Eye Res 2021 - Limbal stem cell diseases (PMID: 33571530)
This is a shared conversation. Sign in to Orris to start your own chat.